国产乱色精品成人免费视频,国产婷婷色一区二区三区在线,八戒八戒午夜视频,国内精品视频一区二区三区八戒

美國(guó)Epitome Biosystems
繼今年2月初以2200萬(wàn)美金成功收購(gòu)Guava Technologies (Guava)*之后，密理博公司再度出資收購(gòu)Epitome Biosystems’ EpiTag?技術(shù)。該項(xiàng)技術(shù)的收購(gòu)將使密理博生物科學(xué)部門進(jìn)一步拓展在multiplex immunoassay液相芯片檢測(cè)方面的實(shí)力，為科學(xué)家提供更廣闊的細(xì)胞信號(hào)傳導(dǎo)解決方案。

密理博公司藥物研發(fā)部門( Drug Discovery) VP, Rick Ryan強(qiáng)調(diào): “ multiplex是密理博公司其中一條增長(zhǎng)最快速的產(chǎn)品線，對(duì)EpiTag技術(shù)的收購(gòu)，將加速產(chǎn)品的發(fā)展以及在市場(chǎng)上的增長(zhǎng)。用戶希望更清楚了解在癌癥，糖尿病等各種疾病中細(xì)胞信號(hào)傳導(dǎo)通路的重要性。EpiTag技術(shù)將使我們深入發(fā)展液相芯片技術(shù)，尤其是在先前細(xì)胞研究中難以檢測(cè)和定量的部分.”

由于缺少對(duì)細(xì)胞內(nèi)目標(biāo)高度特異性的抗體，科學(xué)家一直以來(lái)在推進(jìn)液相芯片細(xì)胞信號(hào)檢測(cè)方面舉步為艱。EpiTag技術(shù)使用分析復(fù)雜生物資料的途徑來(lái)開(kāi)發(fā)高質(zhì)量的抗體，使其更特異，更具選擇性。密理博公司將開(kāi)發(fā)一系列全新的液相芯片免疫檢測(cè)試劑盒，以方便科學(xué)研究者更有效地檢測(cè)、分析蛋白質(zhì)與細(xì)胞信號(hào)通路。

Epitome Biosystems, Inc. develops and commercializes innovative protein measurement products and services to increase the productivity of drug discovery and development. The Company’s products generate valuable information about the cell signaling network, which is a key interface for monitoring drug action and understanding disease. By delivering high-value information on cell signaling networks in a condensed time frame, Epitome’s products and services are driving new research approaches for the development of drugs and diagnostics.

The Company’s products include profiling chips and assay kits, based on proprietary EpiTag? technology, and mass spectrometry-based discovery partnerships (Q-SONAR?). EpiTag? profiling chips and multiplex assays provide highly specific, quantitative measurements of the cell signaling network. Q-SONAR? generates quantitative, broad-based analyses to elucidate cell network dynamics and connectivity, identify potential new targets/biomarkers and more comprehensively assess on- and off-target effects of drugs. Epitome’s technology is validated, scaleable and can be applied broadly across the drug discovery and development continuum and translated to clinical biomarker applications. Epitome partners with pharmaceutical and biotechnology companies to deliver off-the-shelf products and customized solutions.